ADINOLFI, Luigi Elio
 Distribuzione geografica
Continente #
EU - Europa 8.377
NA - Nord America 7.823
AS - Asia 1.623
Continente sconosciuto - Info sul continente non disponibili 20
AF - Africa 16
SA - Sud America 14
OC - Oceania 4
Totale 17.877
Nazione #
US - Stati Uniti d'America 7.783
IE - Irlanda 2.747
UA - Ucraina 1.397
GB - Regno Unito 1.073
IT - Italia 984
DE - Germania 806
CN - Cina 673
SG - Singapore 472
SE - Svezia 432
FI - Finlandia 362
TR - Turchia 327
GR - Grecia 232
FR - Francia 210
KR - Corea 60
IN - India 36
CA - Canada 31
BE - Belgio 29
NL - Olanda 23
EU - Europa 20
RO - Romania 19
RU - Federazione Russa 18
CZ - Repubblica Ceca 17
IR - Iran 17
JP - Giappone 9
ID - Indonesia 7
TW - Taiwan 7
EG - Egitto 6
IL - Israele 6
MX - Messico 6
PL - Polonia 5
BR - Brasile 4
SC - Seychelles 4
AU - Australia 3
CL - Cile 3
CO - Colombia 3
ES - Italia 3
NO - Norvegia 3
PE - Perù 3
PT - Portogallo 3
BG - Bulgaria 2
CH - Svizzera 2
HR - Croazia 2
HU - Ungheria 2
LI - Liechtenstein 2
MK - Macedonia 2
MY - Malesia 2
PK - Pakistan 2
UG - Uganda 2
VN - Vietnam 2
AN - Antille olandesi 1
AR - Argentina 1
AT - Austria 1
BN - Brunei Darussalam 1
BW - Botswana 1
BY - Bielorussia 1
JM - Giamaica 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PA - Panama 1
SA - Arabia Saudita 1
TN - Tunisia 1
TZ - Tanzania 1
UZ - Uzbekistan 1
Totale 17.877
Città #
Dublin 2.741
Jacksonville 2.126
Chandler 1.337
Princeton 422
Roxbury 316
Bremen 304
Singapore 268
Medford 254
Boardman 219
Ann Arbor 218
New York 208
Wilmington 193
Cambridge 186
Woodbridge 186
San Mateo 125
Ashburn 116
Nanjing 108
Beijing 106
Düsseldorf 102
Caserta 96
Des Moines 85
Mountain View 73
Jinan 67
Napoli 65
Seoul 56
Shenyang 54
Naples 42
Norwalk 41
Nanchang 40
Venice 33
Helsinki 31
Brussels 28
Zhengzhou 28
Los Angeles 24
Washington 24
Haikou 23
Milan 23
Tianjin 23
Changsha 21
Houston 21
Auburn Hills 18
Hebei 18
Kunming 18
Ningbo 18
Hangzhou 17
Guangzhou 16
Marano Di Napoli 16
Munich 16
Lanzhou 15
Taizhou 15
Redwood City 14
Shanghai 13
Palermo 12
San Francisco 12
Rome 11
Taiyuan 11
Amsterdam 10
Dearborn 10
Perugia 10
Zanjan 10
Andover 9
Groningen 9
Orange 9
Pozzuoli 9
Sacramento 9
Timisoara 9
Brno 8
Elora 8
Fairfield 8
Ottawa 8
Seattle 8
Torino 8
Toronto 8
Bologna 7
Changchun 7
Hefei 7
Jiaxing 7
Paris 7
Philadelphia 7
Duncan 6
Eboli 6
Florence 6
Gioi 6
London 6
Pune 6
Sesto Calende 6
Tel Aviv 6
Lappeenranta 5
Moscow 5
Taipei 5
Atlanta 4
Avellino 4
Bari 4
Buffalo 4
Cornigliano 4
Grafing 4
Leawood 4
Modugno 4
Montesarchio 4
Mumbai 4
Totale 10.968
Nome #
Sviluppo di un questionario autocompilato per la valutazione delle opinioni dei familiari sulle cause e le conseguenze psicosociali della schizofrenia (QOF) 116
Endocardite da Gemella morbillorum: descrizione di due casi 110
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 109
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 101
Ankle-Brachial Index and cardiovascular events in atrial fibrillation The ARAPACIS Study 95
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 91
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 90
Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis 89
Bioelectrical impedance analysisfor the assessment of body composition in patients with systemic sclerosis 88
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 85
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 82
Ittero in corso di infezione delle vie urinarie. Presentazione di un caso clinico ed aspetti patogenetici 79
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 78
Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study 78
Crioglobulinemia mista essenziale associata a cirrosi epatica: aspetti clinici e terapeutici.Esperienza su una casistica clinica 73
Ruolo eziologico e patogenetico del virus dell'epatite C (HCV) nella crioglobulinemia mista (CM) in pazienti con epatite cronica (EC). 73
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 72
null 71
effetto di concentrazioni subinibenti ed effetto intrafagocitico di aztreonam, cefamandolo e netilmicina 71
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 70
Chronic HCV Infection is risk of atherosclerosis. Role of HCV and HCV-related steatosis 70
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 70
Antimicrobici e sistema immune dell'ospite: bioattività intrafagocitica di antibiotici beta-lattamici 67
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 67
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 66
Chronic HCV infection and neurological and psychiatric disorders: an overview. 64
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 63
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 63
HCV RNA levels in serum, liver and PBMC of chronic hepatitis C patients: pathological and therapeutic significance. 63
Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study 63
All-oral interferon-free treatments: The end of hepatitis C virus story, the dream and the reality 62
Sonoporation by microbubbles as gene therapy approach against liver cancer 62
Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. 61
Activity of aminoglycosides against phagocytosed bacteria 61
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 61
Prevention of the toxicity of erythromycin estolate in the perfused rat liver by endotoxin 60
Resistance to aminoglycosides and other antibiotics among clinical isolates of Enterococcus spp 60
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies 60
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 60
Infective endocarditis due to high-level gentamicin and glycopeptides resistant enterococci: efficacy of the ampicillin-fluoroquinolones combination 60
Celiachia silente in pazienti con epatite C: prevalenza, effetto del trattamento con alfa-interferone sull’attivazione della malattia ed evoluzione clinica 60
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 59
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 59
Aspetti clinico terapeutici della crioglobulinemia mista associata all’epatite cronica C: esperienza su un ampia casistica. 59
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 59
Acute rhabdomiolisys in healthy woman. 59
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 58
Characteristics at presentation and outcome of hepatocellular carcinoma (HCC) in the elderly. A study of the Cancer of the Liver Italian Program (CLIP) 58
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 58
Endotoxin protects against chlorpromazine-induced cholestasis in the isolated perfused rat liver 58
Antimicrobials and biological activities of immune system. Relazione al " Bologna,pag. 3-10. 58
An in-vitro study of treatment of drug-induced cholestasis by tauroursodeoxycholate (TUDC). 58
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 58
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 58
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 57
Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci 57
Disordini immunologici in corso di epatite cronica da HCV: prevalenza significato clinico ed implicazioni terapeutiche. 57
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 57
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 57
Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody 56
PATHOGENESIS AND SIGNIFICANCE OF HCV STEATOSIS.An update on survival strategy of a successful pathogen 56
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 56
Unusually high rate of hepatic comorbidity with Streptococcus bovis endocarditis: trend or coincidence? 56
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 56
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 55
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 55
Effects of bacterial lipopolysaccharide (LPS) on chlorpromazine (CPZ) induced cholestasis in the isolated perfused rat liver 55
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 55
Comunicazione orale: Cinetica precoce dell’HCV-RNA in pazienti con epatite cronica: correlati clinico-virologici e valore predittivo la risposta al trattamento antivirale 55
L'endocardite da Enterococco: nostra esperienza nel periodo 1988-93. 55
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 55
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 55
Steatosi associata ad HCV e steatosi metabolica. Patologie diverse o sovrapposte? 54
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 53
Problemi diagnostici e terapeutici dell'amebiasi: presentazione di due casi clinici 53
Mild chronic hepatitis C with steatosis: Which treatment? 53
Liver's functional alterations produced from erythromycin estolate in the isolated and perfused rat liver 53
Bacterial endotoxin treatment ameliorates erythromycin estolate-induced cholestasis in the isolated perfused rat liver 53
Chronic endotoxin pretreatment protects from the chlorpromazine induced cholestasis 53
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 53
Severe diarrhea occurring during alpha-interferon treatment for chronic hepatitis C is associated with serologic markers of celiac disease 53
Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts 52
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 52
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee 52
Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study 52
Effect of endotoxin tolerance on drug hepatotoxicity: amelioration of taurolithocholate cholestasis in the perfused rat liver 52
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 52
Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. 52
Cholestasis induced by estradiol-17 beta-D-glucuronide: mechanisms and prevention by sodium taurocholate 52
Prevalenza di gentamicina-resistenza (G-R) e suscettibilità antibiotica di enterococchi 52
Major embolic events in infective endocarditis are associated with a younger age 52
Malattie del fegato e delle vie biliari 52
Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. 52
Reduction of taurolithocholic acid-induced cholestasis in the isolated perfused rat liver by endotoxin treatment 51
Bacterial endotoxin effect on liver plasma membranes (LPM): membrane-bound enzymes as probes of the site of interaction 51
Hepatitis C and cardiovascular risk: facts and controversies 51
Discriminating value of serum bile acids in asymptomatic HBsAg carriers 51
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 51
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 51
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 51
Totale 6.267
Categoria #
all - tutte 79.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.839


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.272 0 0 0 17 376 44 444 74 141 61 89 26
2020/20213.116 272 32 362 137 651 34 430 358 16 416 309 99
2021/20222.615 145 9 36 63 889 22 30 67 111 220 222 801
2022/20235.330 468 91 67 401 704 413 17 343 2.569 43 105 109
2023/20242.033 152 71 77 175 731 247 36 64 10 22 142 306
2024/2025214 27 79 87 21 0 0 0 0 0 0 0 0
Totale 18.459